ZFIN Image: Geng et al., 2022, Fig. 2.

Image

Figure Caption

Fig. 2.

Screening for inhibitors of social development identifies fluoroquinolones and other Top2 inhibitors.

(A) Screening workflow. (B) Fluoroquinolones induce social deficits. Comparing DMSO (n = 68, 22, and 82, from left to right) with flumequine (Flum; 25 μM; n = 56), lomefloxacin (Lome; 100 μM; n = 60), ofloxacin (Ofl; 200 μM; n = 22), and oxolinic acid (OA; 200 μM; n = 62). SS, sodium salicylate. (C) The catalytic cycle of Top2 and inhibitors targeting different steps of the cycle. ATP, adenosine 5′-triphosphate; ADP, adenosine 5′-diphosphate. (D to F) Eukaryotic Top2 inhibitors induce social deficits (D). Comparing fish treated with vehicle control (0 μM in each panel); Top2 poisons ellipticine (0 μM: n = 48; 2 μM: n = 31), amsacrine (0 μM: n = 21; 200 μM: n = 20), etoposide (0 μM: n = 24; 10 μM: n = 11), and mitoxantrone (0 μM: n = 38; 5 μM: n = 29) (E); and Top2 catalytic inhibitors aclarubicin (0 μM: n = 22; 8 μM: n = 6), ICRF-193 (0 μM: n = 65; 100 μM: n = 29), and sobuzoxane (0 μM: n = 27; 100 μM: n = 8) (F). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Sci Adv